Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 25, 1337–1338 (1 December 2007) | doi:10.1038/nbt1207-1337
Chinese manufacturers vie for piece of outsourcing pie
Abstract
This September, David Smith, leader of the global manufacturing and supply organization for London-based AstraZeneca, made waves after being quoted in UK newspaper The Times as saying that ten years from now, his firm will have completely outsourced its manufacturing, which would include accessing India and China “in a much more meaningful way.” In the subsequent days AstraZeneca scrambled its spin machine, “clarifying” that the comments “were taken out of context.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
